title: Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.
abstract: Two clinical studies were conducted to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses (intravenous [iv] and subcutaneous [sc]) of blosozumab in postmenopausal women, including prior/current bisphosphonate (BP) users. In these phase 1, randomized, subject- and investigator-blind, placebo-controlled studies, subjects received escalating doses of blosozumab: single iv doses up to 750 mg, single sc doses of 150 mg, multiple iv doses up to 750 mg every 2 weeks (Q2W) for 8 weeks, multiple sc doses up to 270 mg Q2W for 8 weeks, or placebo. Six subjects were randomized to each dose in the single-dose study (12 to placebo) and up to 12 subjects to each arm in the multiple-dose study. Blosozumab was well tolerated with no safety concerns identified after single or multiple administrations up to 750 mg. Dose-dependent responses were observed in sclerostin, N-terminal propeptide of procollagen type 1, bone-specific alkaline phosphatase, osteocalcin, C-terminal fragment of type 1 collagen, and bone mineral density (BMD) after single and multiple (up to 5) administrations of blosozumab. There was up to a 3.41% (p=0.002) and up to a 7.71% (p<0.001) change from baseline in lumbar spine BMD at day 85 after single or multiple administrations of blosozumab, respectively. Prior BP use did not appear to have a clear impact on the effects of single doses of blosozumab when considering bone biomarker and BMD responses. Antibodies to blosozumab were detected by a screening assay, but no patterns with regard to dose or route of administration and no clear impact on blosozumab exposure or PD responses were identified. In summary, blosozumab was well tolerated and exhibited anabolic effects on bone. These findings support further investigation of blosozumab as a potential anabolic therapy for osteoporosis.
authors.affiliation: Eli Lilly and Company, Windlesham, United Kingdom.
authors.forename: Juliet
authors.initials: J
authors.lastname: McColm
authors.forename: Leijun
authors.initials: L
authors.lastname: Hu
authors.forename: Theresa
authors.initials: T
authors.lastname: Womack
authors.forename: Cheng Cai
authors.initials: CC
authors.lastname: Tang
authors.forename: Alan Y
authors.initials: AY
authors.lastname: Chiang
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D015519:Bone Density; D019485:Bone Morphogenetic Proteins / Q000276:immunology*; D005260:Female; D005819:Genetic Markers / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D061067:Antibodies, Monoclonal, Humanized; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; C000593189:blosozumab
keywords: ANABOLICS; BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIALS; DXA; OSTEOPOROSIS